<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
The European Commission has approved Merck & Co Inc’s (NYSE: MRK) Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment of Esophageal Carcinoma or Gastroesophageal Junction (GEJ) Adenocarcinoma. The approval covers patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative GEJ adenocarcinoma whose tumors express PD-L1.
...read full article on Benzinga
